Saito Kazuyuki, Kodama Yasuo, Ono Shunsuke, Mutoh Mizue, Kawashima Susumu, Fujimura Akio
Department of Pharmacology, Division of Clinical Pharmacology, Jichi Medical School, 3311-1 Yakushiji, Minamikawachi-machi, Tochigi 329-0498, Japan.
Contemp Clin Trials. 2005 Aug;26(4):503-9. doi: 10.1016/j.cct.2004.09.004.
The changes in the quality of Japanese clinical trials were evaluated by comparing the results of Good Clinical Practice (GCP) audits conducted from April 1997 to March 2000 (fiscal year (FY) 1997-1999) with those from April 2001 to March 2002 (FY2001). During both of the periods inspections were undertaken by the Organization for Pharmaceutical Safety and Research (OPSR). The audit findings in the former period were based on the audits that covered 331 hospitals and 775 trials conducted under the old GCP guideline. The audits in the latter period targeted 147 hospitals and 238 trials conducted under the old or new GCP guideline. The total number of deficiencies detected by GCP audits in the former three-year period (FY 1997-1999) was 1529, and the corresponding number in the latter single year (FY 2001) was 912. Two remarkable changes in OPSR's findings were observed between FY 1997-1999 and FY 2001 as follows; the proportion of protocol deviations increased from 14.7% (225/1529) to 53.1% (484/912), while the proportion of errors in case report forms (CRFs) decreased from 43.6% (666/1529) to 15.4% (140/912). The new GCP guideline sets very high standards for a hospital's qualification: to have sufficient equipment and hospital resources, to have capacity for promptly responding to urgent trial-related problems, to have an IRB, and to have appropriate staff including clinical research coordinators (CRCs) assigned to the clinical trial. Our results suggest that the impact of the regulatory changes of applicable standard is large for a hospital's qualification for conducting clinical trials in Japan.
通过比较1997年4月至2000年3月(1997 - 1999财年)与2001年4月至2002年3月(2001财年)进行的药品临床试验规范(GCP)审核结果,评估了日本临床试验质量的变化。在这两个时期,审核均由药品安全与研究组织(OPSR)进行。前期的审核结果基于对331家医院和775项按照旧GCP指南开展的试验的审核。后期的审核针对147家医院以及按照旧GCP指南或新GCP指南开展的238项试验。前三年期间(1997 - 1999财年)GCP审核发现的缺陷总数为1529项,而在后期单一年度(2001财年)相应的数字为912项。在1997 - 1999财年和2001财年之间,OPSR的审核结果出现了两个显著变化,如下所示:方案偏离的比例从14.7%(225/1529)增至53.1%(484/912),而病例报告表(CRF)中的错误比例从43.6%(666/1529)降至15.4%(140/912)。新GCP指南对医院资质设定了非常高的标准:要有充足的设备和医院资源,要有迅速应对与试验相关紧急问题的能力,要有伦理审查委员会(IRB),并且要有包括分配到临床试验的临床研究协调员(CRC)在内的合适人员。我们的结果表明,适用标准的监管变化对日本医院开展临床试验的资质影响很大。